anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Acute hepatic failure and severe liver injury, in some cases fatal, have been reported in patients treated with KETEK. These hepatic reactions included fulminant hepatitis and hepatic necrosis leading to liver transplant, and were observed during or immediately after treatment. In some of these cases, liver injury progressed rapidly and occurred after administration of a few doses of KETEK. (See ADVERSE REACTIONS) 

Physicians and patients should monitor for the appearance of signs or symptoms of hepatitis, such as fatigue, malaise, anorexia, nausea, jaundice, bilirubinuria, acholic stools, liver tenderness or hepatomegaly. Patients with signs or symptoms of hepatitis must be advised to discontinue KETEK and immediately seek medical evaluation, which should include liver function tests. (See ADVERSE REACTIONS, PRECAUTIONS, Information to Patients.) If clinical hepatitis or transaminase elevations combined with other systemic symptoms occur, KETEK should be permanently discontinued.

Ketek must not be re-administered to patients with a previous history of hepatitis and/or jaundice associated with the use of KETEK tablets, or any macrolide antibiotic. (See CONTRAINDICATIONS)

In addition, less severe hepatic dysfunction associated with increased liver enzymes, hepatitis and in some cases jaundice was reported with the use of KETEK. These events associated with less severe forms of liver toxicity were reversible.
The invention relates to a medicament for treating neuronal damage diseases, in particular to a muscle fringing and marrow benefiting neuronal capsule. The medicament is prepared from ginkgo leaf, cartialgenous, processed semen strychni, cynomorium songaricum, tiger narrow, balanophoora involucrate hook.f, worm grass, rhizoma acori graminei, rhizoma alismatis, radix achyranthis bidentatae, uncaria rhynchophylla, scorpin, lucid ganoderma, acanthopanax root, Chinese angelica, red flower, astragalus membranaceus, codonopsis pilosula, dates, stiff silkworm, donkey-hide gelatin, bezoar, Shaluozi, hindu datura flower, rhizoma gastrodiae, large-leaved gentian, radix polygonati officinalis, licorice root, radix clematidis, rhizoma wenyujin concisum, caulis sinomenii, isatis root and ginseng in a certain proportion. The raw materials by the are soaked in yellow wine firstly, and then dried in the air instead of by roasting or under the blazing sun for quite a long time, and finally processed into capsule preparations easy to take. The medicament can fringe muscles, benefit narrows, nourish nerves, generate muscles, enhance muscle force and reduce nervous symptoms. When the medicament is used for treating neuronal damage diseases, the clinical curative effect is higher than that of the Methycobal, narrow benefiting granules and the import drug Rilutek. Proved by more than ten years of clinical applications, the effective rate is higher than 95 percent, and the cure rate of early patients is higher.
Each subject will receive mepolizumab 300 mg subcutaneous (SC) injection every 4 weeks (13 administrations) along with standard care. It will be administered as 3 separate injections (100 mg each- total dose 300 mg); individual injection sites will be separated by at least 5 cm. It will be administered into any of the upper arm, thigh or anterior abdominal wall.
Dose escalation will begin with young adult/adolescent patients. The initial two patients enrolled in the study will be \> 15 years of age. These patients must complete the entire 28-day period of treatment at Dose Level 1 prior to additional young adult/adolescent patients being enrolled. All 4 young adult/adolescent patients must complete 28 days of treatment at Dose Level 1, and cumulative safety must be reviewed by the Safety Review Committee (SRC), prior to the enrollment of pediatric patients. The initial two pediatric patients enrolled will be \> 6 years of age. These patients must complete the entire 28-day period of treatment at Dose Level 1 prior to additional pediatric patients being enrolled. A minimum of 8 and maximum of 12 pediatric patients will be enrolled to allow for at least 4 patients between the ages of 3-6.

Study assessments will be conducted at each visit. Patients will be observed closely for Dose Limiting Toxicity (DLT) during each dosing period. Any patient experiencing a DLT will have study drug interrupted and will not be allowed to escalate to the next higher dose level. The patient may resume treatment at one dose level lower once the DLT has resolved to baseline or to ≤ Grade 1 in severity. The MTD will be defined as the dose level immediately below the dose level at which DLT occurred. Patients requiring an interruption in treatment of \> 3 weeks following a DLT will be withdrawn from the study. The MTD will be assessed separately for each individual patient.

Following the completion of dose escalation, each patient will continue treatment at either the highest dose or their individual MTD, and then transition to the OBD for their age group (once defined), for a total of 3 months. Patients failing to receive 75% of planned doses for reasons other than adverse effects may be replaced.
The invention comprises 9-diethylaminomethyl -9, 10-dihydro -9, 10-ethano-(1, 2)-anthracene and its acid addition salts, and their preparation by reducing 9, 10-dihydro-9, 10-ethano-(1, 2)-anthracene -9-carboxylic acid diethylamide with lithium aluminium hydride followed by conversion of any resulting free base into an acid addition salt or of acid addition salt into free base, as required. 9, 10-Dihydro -9, 10-ethano-(1, 2)-anthracene-9-carboxylic acid diethylamide is made by treating the free acid with thionyl chloride and reacting the resulting acid chloride with diethylamine. Pharmaceutical preparations for use as tranquilizers comprise the above compounds of the invention, i.e. the free base or the salts with organic or inorganic acids, including therapeutically useful substances such as salicylic, aminosalicylic or ascorbic acid, tryptophan, lysine or arginine, in admixture or conjunction with a solid or liquid carrier suitable for enteral (e.g. oral) or parenteral administration.  The preparations may take the form of tablets, dragees, capsules, suspensions or emulsions and may contain preserving, stabilizing, wetting or emulsifying agents, salts for regulating osmotic pressure or buffers.
AT13148 is a new drug which looks promising in laboratory studies. We now wish to find out if it will be useful in treating patients with cancer. AT13148 is a type of drug called a protein kinase inhibitor. It blocks several different chemical messengers (enzymes) called AGC kinase proteins. These chemical messengers are part of the signaling process within cells which can make cells produce chemicals that trigger and control cell growth and cell death. In some types of cancer these chemical messengers are 'switched on' or 'switched off' permanently due to changes in the genes of cells called "gene mutations" leading to uncontrolled cancer cell growth. AT13148 targets multiple protein kinases from three families of kinases unlike many of the other protein kinase inhibitors currently being tested which target just one or two kinases. This may mean that it will work better and in a wider group of cancer patients. Patients will not be selected to take part based on having these gene mutations for this first trial because we want to learn more about which mutations are most important but this would be the hope for future trials. The patient population anticipated to benefit from this drug includes certain types of breast, prostate and ovarian cancer which more commonly have these gene mutations.
Compositions and methods for treating skin redness. According to one embodiment, the present invention is a topical skin care composition having a dermatologically acceptable carrier, such as water, and a plurality of ingredients dissolved in the carrier. The components comprise: a mixture of natural oils; a plurality of vitamins; and 0.1-1 wt% of salicylphytosphingosine. The composition is not suitable for application to the eyelid or ocular region. The natural oil mixture comprises: aloe vera leaf juice extract; coconut butter (coconut oil); a hydrolyzed glycosaminoglycan; and caprylic/capric triglyceride. The multivitamins are selected from the group consisting of vitamin C, vitamin E, salts/derivatives of vitamin C and vitamin E, and mixtures thereof. In one aspect, the multivitamins include: sodium ascorbyl phosphate; disodium dodecyl iminodipropionate tocopheryl phosphate; and jojoba oil.
This study targets a population of patients with symptomatic PAD (CLTI or severe claudication in 1:1 ratio) and no prior cardiac history, no myocardial infarction, no coronary angiography or coronary computed tomography angiography (CTA), and no coronary revascularization (PCI or CABG) who have undergone successful lower extremity revascularization with planned post-operative best medical therapy. Within 14 days following lower-extremity revascularization, patients will be randomly assigned to BMT alone or BMT plus coronary CT angiography (which must be completed within 14 days of randomization) and Fractional Flow Reserve Derived from CT (FFRct) analysis to determine the functional significance of coronary lesions identified on the CT scan. Results of the CT scan and FFRCT analysis in patients randomized to the CT-FFRct group, will be provided to treating physicians to help guide patient management with Heart Team consideration for coronary angiography and revascularization as appropriate for each patient. Coronary revascularisation (PCI or CABG), if indicated, is strongly recommended within 3 months from the randomisation. Clinical follow up (based on date of randomization) is planned 6 months, one and 2 years. Additional long-term follow up out to 5-years is planned for participating centers. An independent academic clinical events committee will adjudicate all endpoints in a blinded manner. The definition of outcome events will be in accordance with Academic Research Consortium-2 consensus document.
Epigastric pain is chronic, periodic and rhythmic superior belly pain. Gastric ulcer pain and duodenal ulcer pain are mostly occurred 1-4 hours after a meal. Rhythmicity, and belching and acid saliva spiting symptoms of the epigastric pain are severe than that of the gastric ulcer. During pain, the pain can be relieved by eating food or taking an alkaline medicine. The epigastric pain is liable to attack because of fatigue and improper diet and in autumn and winter. If excrement has a blackened color like pitch or if vomituses are dark brown, the superior belly is uncomfortable and the face of a person is pale, then the person has gastric bleeding or duodenal bleeding. The effective prescription adopts Chinese herbal medicines as raw materials. Juice is extracted by a traditional medicine decocting method and is orally taken. The effective prescription has no toxic or side effects, and has unique treating effects. The suitable scope of the effective prescription comprises flowing symptoms: superior belly pain, stomachache, acid saliva belching, ulcer and bleeding, heart and belly cold and pain, and the like. Based on repeated practice for a plurality of years and clinical observation of hundreds of cured patients, the curative rate of the effective prescription is 94%, and the effective prescription has obvious functions of regulating the center, short curative period, rapid effectiveness and good consolidation. The prescription provided by the invention is the only effective prescription for treating the epigastric pain.
This invention relates to methods of treatment of persons and animals with indications of immuno-deficiency, wherein the said indication is resultant from viral and/or retroviral, bacterial, fungal or parasitic infection and/or plus infectious protein units. Herein is described the method of administration of an agonist or antagonist to Th2 cytokines in combination with anti-viral agents or immune enhancing agents. In one aspect of the invention, the agonist or antagonist is a receptor to Interleukin-4 (or mutein receptor) which is administered in combination with an anti-viral agent. Preferred anti-viral/immune-enhancing agents include (a) 'compounds of Formula I' (defined herein), and metabolites, analogs and precursors thereof, and pharmaceutically acceptable salts of any such compounds, metabolites, analogs and precursors, (b) protease inhibitors, and (c) reverse transcriptase inhibitors. Additionally herein is described a method of enhancing viral replication as a means of exposing latent infection by the administration of an agonist or antagonist to a Th2 cytokine. There are also provided such methods comprising administering to a patient at least one Th2 cytokine and at least one agonist and/or at least one antagonist to said Th2 cytokine. There are also provided compositions and kits for use in such methods, as well as the use of such compounds in the manufacture of medicaments for treatment for various conditions.
To acquire an image that allows a user to identify what image it is.SOLUTION: An information processing apparatus comprises a first image acquisition unit, a setting unit, a second image acquisition unit, a partial image acquisition unit, and a storage unit. The first image acquisition unit acquires a first image of a pathological sample or a pathological specimen photographed by a photographing device. The setting unit sets a partial area to the first image. The second image acquisition unit acquires a second image of the pathological sample or the pathological specimen photographed by the photographing device. The partial image acquisition unit acquires a partial image that is an image of an area in the second image corresponding to the partial area. The storage unit stores the second image and the partial image in association with each other.SELECTED DRAWING: Figure 1
Monitoring of intracranial pressure (ICP) has been used in the management of patients with increased ICP, or in whom increased ICP was suspected. ICP depends on the relative constancy of total volume inside the skull, comprising cerebrospinal fluid (CSF), blood, and brain tissue. The changes of CSF volume affect the ventricular fluid pressure and defined it as volume pressure response (VPR). The shape or curve of the intracranial volume-pressure (V-P) relationship is well known in daily neurosurgical practice. If the P-V curve can be expressed by mathematic manner, then there should be an indicator to reflect the status of the curve. This study is conducted in order to understand the difference of each P-V curve in patients with increased intracranial pressure. The individual VPR values have been tested with three mathematical models (linear, parabolic and exponential regression equation).
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) develops from very early cells with the potential for both T-cell and myeloid differentiation. The ambiguous nature of leukemic blasts in ETP-ALL may lead to immunophenotypic alterations at relapse. Here, we address immunophenotypic alterations and related classification issues, as well as genetic features of relapsed pediatric ETP-ALL. Between 2017 and 2022, 7518 patients were diagnosed with acute leukemia (AL). In addition to conventional immunophenotyping, karyotyping, and FISH studies, we performed next-generation sequencing of the T-cell receptor clonal repertoire and reverse transcription PCR and RNA sequencing for patients with ETP-ALL at both initial diagnosis and relapse. Among a total of 534 patients diagnosed with T-cell ALL (7.1%), 60 had ETP-ALL (11.2%). Ten patients with ETP-ALL experienced relapse or progression on therapy (16.7%), with a median time to event of 5 months (ranging from two weeks to 5 years). Most relapses were classified as AL of ambiguous lineage (n = 5) and acute myeloid leukemia (AML) (n = 4). Major genetic markers of leukemic cells remained unchanged at relapse. Of the patients with relapse, four had polyclonal leukemic populations and a relapse with AML or bilineal mixed-phenotype AL (MPAL). Three patients had clonal TRD rearrangements and relapse with AML, undifferentiated AL, or retention of the ETP-ALL phenotype. ETP-ALL relapse requires careful clinical and laboratory diagnosis. Treatment decisions should rely mainly on initial examination data, taking into account both immunophenotypic and molecular/genetic characteristics.
The present invention relates to a quantitative method for detecting yessotoxins in fishery products based on the activation the toxin produces on cellular phosphodiesterases and the therapeutic use of this activation. The cellular target of yessotoxin (YTX) and its analogs is the activation of phosphodiesterases (PDEs). The PDEs-YTX bond produces a measurable signal. The bond can be quantified by means of an affinity biosensor or by fluorescence. The biosensor detects biomolecular interactions and allows determining the presence of YTX due to its interaction with PDEs. The variations in the degradation rate of the fluorescent derivative anthraniloyl-cAMP are determined by means of plate fluorescence. The rate at which the PDEs degrade this molecule increases in the presence of YTX. YTX inhibits immunological activation of mastocytes in rats and induces a cytotoxic effect in human hepatocarcinoma cells, which implies two therapeutic uses of YTXs as an antiallergic and antitumor compound.
The process of cancer metastasis is dependent on the cancer cells' capacity to detach from the primary tumor, endure in a suspended state, and establish colonies in other locations. Anchorage dependence, which refers to the cells' reliance on attachment to the extracellular matrix (ECM), is a critical determinant of cellular shape, dynamics, behavior, and, ultimately, cell fate in nonmalignant and cancer cells. Anchorage-independent growth is a characteristic feature of cells resistant to anoikis, a programmed cell death process triggered by detachment from the ECM. This ability to grow and survive without attachment to a substrate is a crucial stage in the progression of metastasis. The recently discovered phenomenon named "adherent-to-suspension transition (AST)" alters the requirement for anchoring and enhances survival in a suspended state. AST is controlled by four transcription factors (IKAROS family zinc finger 1, nuclear factor erythroid 2, BTG anti-proliferation factor 2, and interferon regulatory factor 8) and can detach cells without undergoing the typical epithelial-mesenchymal transition. Notably, AST factors are highly expressed in circulating tumor cells compared to their attached counterparts, indicating their crucial role in the spread of cancer. Crucially, the suppression of AST substantially reduces metastasis while sparing primary tumors. These findings open up possibilities for developing targeted therapies that inhibit metastasis and emphasize the importance of AST, leading to a fundamental change in our comprehension of how cancer spreads.
This is a phase II trial designed to provide a transplant option for patients with rare poor-prognosis cancers. The protocol is only open to patients with metastatic or relapsed cancers for whom the probability of remaining free of progressive disease for one year after being brought into remission is \< 25%. Patients eligible for this study have been diagnosed with a form of cancer that leads to death more than 75% of the time when treated with standard therapy doses of chemotherapy and/ or radiation therapy. Under this treatment intensification protocol the expectation is that the one year progression-free survival for this group of patients will rise to 40%. Patients eligible for this protocol will be followed for one year post-transplant. Patients alive and free of progressive disease at the end of this period will be considered successes.
Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken preoperatively. Starting on postoperative day (POD) 1, patients will take one capsule once a day until end of POD14.
The invention relates to a method for preparing a reagent for curing serious rheumatoid arthritis. Rheumatism is a frequently encountered disease. Due to the wet climate of the south, the disease rate is high, so that the physical and mental health of people is seriously affected. Although many reagents for curing rheumatoid arthritis are available presently, ideal curing effect can not be reached. The method aims to develop a reagent with obvious effect, which is produced by twenty nine Chinese herbal medicines including glassleaved sweetflag rhizome, radix sileris, myrrh, sulphuric rhizoma arisaematis, asarum, dried ginger, curcuma longa, clove bud, sargentgloryvine stem, Platycodon grandiflorus branch, radix aconiti kusnezoffi, caltrop, red shaw, atractylode, notopterygium, paniculate swallowwort, morinda officinalis, pubescent angelica, sulphuric pangolin, Chinese prickly ash, rhizoma kaempfferiae, homalonemae rhizoma, clematis root, ephedra, prepared monkshood, madder, safflower, rhubarb etc. After decades of clinical application, the reagent has obvious efficacy, without toxic or side effect.
Objective: Combination therapy, including inhaled corticosteroids (ICS), is often prescribed as initial treatment for Chronic Obstructive Pulmonary Disease (COPD) despite limited evidence that ICS therapy is beneficial. Prescribing rates exceed the estimated number of candidates diagnosed with COPD who are eligible for ICS treatment per guideline-directed therapy. Therefore, some patients would benefit from ICS withdrawal due to potentially inappropriate prescribing. This review aims to highlight evidence evaluating ICS withdrawal approaches in COPD. Methods: A comprehensive literature review was performed between June 2021 and March 2022 with assistance from a reference librarian. Sources of literature review include PubMed and Embase. The authors selected randomized controlled trials and articles evaluating ICS withdrawal approaches in patients with COPD. Three clinical trials and one post-hoc analysis are discussed in this review. Pertinent safety, efficacy, and statistical and clinical outcomes are summarized. Conclusions: The most appropriate approach to de-prescribe ICS maintenance therapy in COPD without clear indication remains uncertain. Pharmacists can play a role in optimizing clinical outcomes by analyzing ICS use in practice and identifying potential candidates for ICS withdrawal. The withdrawal protocols discussed in this review offer options for clinicians to help guide therapy decisions.
Consenting patients undergoing lung resection will receive standard postoperative thromboprophylaxis in hospital until the time of discharge. Subsequently, patients will be administered LMWH for duration of 30 days as outpatients.
Expressing Left-Right relations is challenging for speaking-children. Yet, this challenge was absent for signing-children, possibly due to iconicity in the visual-spatial modality of expression. We investigate whether there is also a modality advantage when speaking-children's co-speech gestures are considered. Eight-year-old child and adult hearing monolingual Turkish speakers and deaf signers of Turkish-Sign-Language described pictures of objects in various spatial relations. Descriptions were coded for informativeness in speech, sign, and speech-gesture combinations for encoding Left-Right relations. The use of co-speech gestures increased the informativeness of speakers' spatial expressions compared to speech-only. This pattern was more prominent for children than adults. However, signing-adults and children were more informative than child and adult speakers even when co-speech gestures were considered. Thus, both speaking- and signing-children benefit from iconic expressions in visual modality. Finally, in each modality, children were less informative than adults, pointing to the challenge of this spatial domain in development.